COCRYSTAL PHARMA NEW O.N. (F:8CC) — Stock Price
COCRYSTAL PHARMA NEW O.N. (F:8CC) is currently trading at €0.89 EUR, up 2.89% today. Over the past 52 weeks, shares have ranged between €0.69 and €1.43. This page tracks COCRYSTAL PHARMA NEW O.N.'s live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 8CC stock market capitalisation.
COCRYSTAL PHARMA NEW O.N. (8CC) Stock Price Chart — Daily History & Trading Volume
The chart below tracks COCRYSTAL PHARMA NEW O.N.'s daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
COCRYSTAL PHARMA NEW O.N. Income Statement — Revenue, Profit & Earnings by Year
COCRYSTAL PHARMA NEW O.N.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | €5.05 Million | €12.54 Million | €15.17 Million | €12.39 Million | €8.79 Million |
| SG&A | €3.96 Million | €5.34 Million | €5.99 Million | €5.75 Million | €5.43 Million |
| Total Operating Expenses | €9.02 Million | €17.88 Million | €21.16 Million | €18.14 Million | €14.22 Million |
| Operating Income | €-9.02 Million | €-17.88 Million | €-21.16 Million | €-18.14 Million | €-14.22 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | — | — | — | €2.00K | €4.00K |
| Income Before Tax | €-8.83 Million | €-17.50 Million | €-17.98 Million | €-38.84 Million | €-14.19 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-8.83 Million | €-17.50 Million | €-17.98 Million | €-38.84 Million | €-14.19 Million |
COCRYSTAL PHARMA NEW O.N. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes COCRYSTAL PHARMA NEW O.N.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €9.71 Million | €13.46 Million | €31.26 Million | €40.84 Million | €79.39 Million |
| Total Current Assets | €8.13 Million | €11.58 Million | €29.09 Million | €40.18 Million | €59.32 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | — | — | — | — | €0.00 |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | €0.00 | €19.09 Million |
| Total Liabilities | €3.38 Million | €3.93 Million | €4.88 Million | €1.27 Million | €1.84 Million |
| Total Current Liabilities | €2.21 Million | €2.43 Million | €3.26 Million | €1.22 Million | €1.54 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €6.33 Million | €9.52 Million | €26.38 Million | €39.57 Million | €77.55 Million |
| Retained Earnings | €-342.25 Million | €-333.42 Million | €-315.91 Million | €-297.93 Million | €-259.09 Million |
COCRYSTAL PHARMA NEW O.N. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how COCRYSTAL PHARMA NEW O.N. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-8.19 Million | €-16.48 Million | €-14.67 Million | €-21.43 Million | €-12.72 Million |
| Capital Expenditures | €12.00K | €8.00K | €118.00K | €74.00K | €52.00K |
| Free Cash Flow | €-8.20 Million | €-16.49 Million | €-14.78 Million | €-21.51 Million | €-12.77 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €5.37 Million | €0.00 | €3.99 Million | €-27.00K | €38.47 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €270.00K | €643.00K | €801.00K | €855.00K | €724.00K |
| Depreciation | €376.00K | €446.00K | €-1.39 Million | €388.00K | €382.00K |
| Change in Cash | €-2.83 Million | €-16.49 Million | €-10.79 Million | €-21.54 Million | €25.70 Million |
COCRYSTAL PHARMA NEW O.N. Earnings History — EPS Actual vs. Analyst Estimates
Track COCRYSTAL PHARMA NEW O.N.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 13, 2026 | — | — | — |
| Mar 30, 2026 | — | — | — |
| Nov 11, 2025 | — | — | — |
| May 12, 2025 | — | — | — |
| Mar 26, 2025 | — | — | — |
| Nov 11, 2024 | — | — | — |
| May 15, 2023 | -0.59 | — | — |
| Mar 29, 2023 | -0.54 | — | — |